Advertisement

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Philippe Rousselot, Francoise Huguet, Delphine Rea, Laurence Legros, Jean Michel Cayuela, Odile Maarek, Odile Blanchet, Gerald Marit, Eliane Gluckman, Josy Reiffers, Martine Gardembas and François-Xavier Mahon

Data supplements

  • Supplemental materials for: Rousselot et al, Vol 109, Issue 1, 58-60

    Participating members of the Intergroupe Fran�ais des Leucémies Myéloïdes Chronique (FIφLMC)

    ATTAL Michel, Toulouse, France
    BARBU Véronique, Paris, France
    BERTHOU Christian, Brest, France
    BLAISE Didier, Marseille, France
    BORIES Dominique, Créteil, France
    BRIERE Jean, Paris, France
    BUZIN Agnès, Paris, France
    CAILLOT Denis, Dijon, France
    CASASSUS Philippe, Bobigny, France
    CAYUELA Jean Michel, Paris, France
    CHARRIN Christiane, Lyon, France
    CONY-MACKHOUL Pascale, Annecy, France
    CORM Sélim, Lille, France
    DASTUGUE Nicole, Toulouse, France
    DEVERGIE Agnès, Paris, France
    ETIENNE Gabriel, Bordeaux, France
    FACON Thierry, Lille, France
    FOUILLARD Loïc, Paris, France
    GARDEMBAS Martine, Angers, France
    GAUB Marie Pierre, Strasbourg, France
    GIRAUDIER Stéphane, Créteil, France
    GLUCKMAN Eliane, Paris, France
    GOLDSCHMIDT Emma, Villejuif, France
    GUERCI Agnès, Nancy, France
    GUILHOT Fran�ois, Poitiers, France
    GUYOTAT Denis, Saint-Etienne, France
    HAROUSSEAU Jean Luc, Nantes, France
    HAVET LOISEAU Hervé, Nantes, France
    HAYETTE Sandrine, Lyon, France
    HUGUET Fran�oise, Toulouse, France
    IFRAH Norbert, Angers, France
    JONVEAUX Philippe, Nancy, France
    JOUET Jean Pierre, Lille, France
    KILADJIAN Jean Jacques, Bobigny, France
    LACORTE Jean Marc, Paris, France
    LAI Jean Luc, Lille, France
    LEGROS Laurence, Nice, France
    LEPORRIER Michel, Caen, France
    MAAREK Odile, Paris, France
    MAHON Fran�ois Xavier, Bordeaux, France
    MALOISEL Frédéric, Strasbourg, France
    MICHALLET Mauricette, Lyon, France
    MOSSAFA Hossein, Paris, France
    NAJMAN Albert, Paris, France
    NICOLINI Franck, Lyon, France
    PAUTAS CHAMBON Cécile, Créteil, France
    PEROT Christine, Paris, France
    PREUDHOMME Claude, Lille, France
    RAYNAUD Sophie, Nice, France
    REA Delphine, Paris, France
    REIFFERS Josy, Bordeaux, France
    RIO Bernard, Paris, France
    ROUSSELOT Philippe, Versailles, France
    ROY Lydia, Poitiers, France
    SPENTCHIAN Marc, Versailles, France
    TERRE Christine, Versailles, France
    TULLIEZ Michel, Créteil, France
    TURHAN Ali, Poitiers, France
    VANDENAKKER Jacqueline, Paris, France
    VARET Bruno, Paris, France
    VIGIER Magda, Nantes, France

    Article Figures & Data

    Tables

    • Table 1

      Patient characteristics

      Pt no.Age, ySexCML phaseSokal scorePrevious therapyIFN duration, moBest response to IFNLast response at start of IMIM treatment duration for undetectable BCR-ABL transcripts, moIM treatment duration with a negative RTQ-PCR, moReappearance of BCR-ABL transcripts (level, %*)Duration of undetectable BCR-ABL transcripts, moIM treatment duration after molecular relapse, mo/last RTQ-PCR result, %
      142FCPLIM + Ara-C0No Resp1026Yes (0.02)37/undetec
      254MCPLIM + Ara-C0No Resp1730Yes (0.3)24/0.015
      375FCPHHU + IFN9No RespNo Resp1145Yes (0.015)19/0.001
      483FCPIHU + IFN29No RespNo Resp1145Yes (0.01)26/0.002
      573MAPIFN63mCRmCR1442Yes (0.002)18/undetec
      658FCPLIFN71CCRNo Resp527Yes (0.03)51/0.03
      776MCPIIFN + Ara-C29mCRNo Resp1432No22
      868MCPIIFN29CCRNo Resp444No9
      958FCPIIFN + Ara-C and AHSCT32mCRNo Resp1624No24
      1071MCPLHU + IFN and AHSCT33CCRPCgR1134No21
      1166FCPLIFN67CCRPCgR532No15
      1278MCPIIFN152CCRNo Resp632No9
      • Pt indicates patient; CML, chronic myelogenous leukemia; IFN, recombinant interferon alpha; IM, imatinib mesylate; CP, chronic-phase CML; L, low Sokal score; Ara-C, cytarabine; —, not applicable; No Resp, absence of cytogenetic response; undetec, undetectable BCR-ABL transcript; H, high Sokal score; HU, hydroxyurea; I, intermediate Sokal score; AP, accelerated-phase CML; mCR, minor cytogenetic response; CCR, complete cytogenetic response; AHSCT, autologous hematopoietic stem cell transplantation; PCgR, partial cytogenetic response.

      • * Normalized level of BCR-ABL/ABL ratio.

      • Last follow-up with undetectable BCR-ABL transcript.